ClinicalTrials.gg
WithdrawnNCT04859582Updated Dec 16, 2021

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

A Phase 3 interventional study of Pembrolizumab and Cisplatin in Stomach Neoplasms, sponsored by Merck Sharp & Dohme LLC. Withdrawn at 28 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Withdrawn due to protocol amendment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Nov 2018, registered Apr 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing pembrolizumab in Stomach Neoplasms — 7 open to participants now, 13 under way, 1 of them phase 3. pembrolizumab · Stomach Neoplasms.

Enrollment
40th of 41
0 · median 41
Started
2018
with 7 others
Phase 3
10 of 41
1 open now
Registered
33rd of 41
by date
Lead sponsor
12 of 41
Merck Sharp & Dohme LLC

Among the 41 studies testing pembrolizumab in Stomach Neoplasms, this one is the 40th largest by enrollment, is one of 8 that started in 2018, is one of 10 in phase 3, and was the 33rd registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

7 of the 41 studies testing pembrolizumab in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing pembrolizumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen]) versus placebo in combination with chemotherapy (FP or CAPOX regimens) in the treatment of human epidermal growth factor receptor 2 (HER2) negative advanced gastric or GEJ adenocarcinoma in adult Chinese participants.

The primary hypotheses of this study are that pembrolizumab plus chemotherapy is superior to placebo plus chemotherapy in terms of overall survival (OS).

Read the detailed description

The China extension study will include participants previously enrolled in China in the global study for MK-3475-859 (NCT03675737) plus those enrolled during the China extension enrollment period. A total of approximately 231 Chinese participants will be enrolled.

03

Conditions studied

  • Stomach Neoplasms

Browse trials for

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death ligand 1 (PD-L1, PDL1)
  • programmed cell death ligand 2 (PD-L2, PDL2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed diagnosis of locally advanced unresectable or gastric or gastroesophageal junction (GEJ) adenocarcinoma with known programmed cell death ligand 1 () expression status
  • Has human epidermal growth factor receptor 2 () negative cancer
  • Male participants must agree to use during the intervention period and for at least 95 days after the last dose of chemotherapy, refrain from donating sperm and be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent or must agree to use contraception per study protocol unless confirmed to be azoospermic during this period
  • Female participants who are not pregnant, not breastfeeding, and at least one of the following conditions applies: not a woman of (WOCBP) OR is a WOCBP who agrees to use contraception or be abstinent from heterosexual intercourse as their preferred and usual lifestyle during the treatment period and for at least 180 days after the last dose of chemotherapy or for at least 120 days after the last dose of pembrolizumab, whichever is last, and agrees not to donate eggs to others or freeze/store for her own use for the purpose of reproduction during this period
  • Has per version 1.1 (RECIST 1.1) as assessed by investigator assessment
  • Has provided sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
  • Has provided tumor tissue sample deemed adequate for PD-L1 biomarker analysis
  • Has provided tumor tissue sample for microsatellite instability (MSI) biomarker analysis
  • Has an (ECOG) performance status of 0 or 1 within 3 days prior to the start of study intervention
  • Has adequate organ function as demonstrated by laboratory testing within 10 days prior to the start of study treatment

Exclusion criteria

Exclusion Criteria

  • Has squamous cell or undifferentiated gastric cancer
  • Has had major surgery, open , or significant traumatic injury within 28 days prior to randomization, anticipation of the need for major surgery during the course of study intervention, or has not recovered adequately from the toxicity and/or complications from previous surgery
  • Has preexisting peripheral neuropathy >Grade 1
  • Is a who has a positive urine pregnancy test within 72 hours prior to randomization or treatment allocation
  • Has had previous therapy for locally advanced, unresectable or gastric/GEJ cancer. Participants may have received prior and/or adjuvant therapy as long as it was completed ≥6 months prior to randomization
  • Has received prior therapy with an , anti-PD-L1 or anti- PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX- 40, CD137)
  • Has received prior systemic anticancer therapy including agents within 4 weeks prior to randomization or has not recovered from all AEs due to any previous therapies to ≤Grade 1 or baseline
  • Has received prior radiotherapy within 2 weeks prior to study start or has not recovered from all previous radiation-related toxicities, required , and have not had radiation pneumonitis. A 1-week is permitted for palliative radiation (≤2 weeks of radiotherapy) to noncentral nervous system (CNS) disease
  • Has received a live or within 30 days prior to the first dose of study treatment
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of therapy within 7 days prior to the first dose of study treatment
  • Has a known additional that is progressing or has required active treatment within the past 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy
  • Has known active and/or carcinomatous meningitis
  • Has severe (≥Grade 3) to pembrolizumab and/or any of its
  • Has an active disease that has required systemic treatment in past 2 years
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Has an active infection requiring systemic therapy
  • Has a known history of (HIV) infection
  • Has a known history of (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as Hepatitis C virus [HCV] ribonucleic acid [RNA] detected qualitatively) infection
  • Has a known history of active tuberculosis
  • Has hypokalemia (serum potassium less than the lower limit of normal)
  • Has hypomagnesemia (serum magnesium less than the lower limit of normal)
  • Has hypocalcemia (serum calcium less than the lower limit of normal)
  • Has a history or current evidence of any condition (eg, known deficiency of the enzyme dihydropyrimidine dehydrogenase), therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is last
  • Has had an allogenic tissue/solid organ transplant
  • Has a known severe hypersensitivity (≥ Grade 3) to any of the study chemotherapy agents (including, but not limited to, infusional 5-fluorouracil or oral capecitabine) and/or to any of their excipients
  • For participants taking cisplatin: has Grade ≥2 audiometric hearing loss
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + FP or CAPOX

    Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m\^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m\^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m\^2 IV on Day 1 Q3W + capecitabine 1000 mg/m\^2 orally twice a day (BID) on Days 1 to 14 Q3W. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).

    Biological: Pembrolizumab · Drug: Cisplatin · Drug: 5-fluorouracil · Drug: Oxaliplatin · Drug: Capecitabine

  • Active comparator
    Placebo + FP or CAPOX

    Participants receive placebo for pembrolizumab IV on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m\^2 IV on Day 1 Q3W and 5FU 800 mg/m\^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m\^2 IV on Day 1 Q3W + capecitabine 1000 mg/m\^2 orally BID on Days 1 to 14 Q3W.

    Drug: Cisplatin · Drug: 5-fluorouracil · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Placebo for Pembrolizumab

Interventions

  • BiologicalPembrolizumab

    Administered as an IV infusion on Day 1 Q3W

    Also known as: KEYTRUDA®, MK-3475

  • Administered as an IV infusion on Day 1 Q3W

    Also known as: PLATINOL®

  • Administered as a continuous IV infusion on Days 1-5 Q3W

    Also known as: ADRUCIL®, 5FU

  • Administered as an IV infusion on Day 1 Q3W

    Also known as: ELOXATIN®

  • Administered orally BID on Days 1 to 14 Q3W

    Also known as: XELODA®

  • DrugPlacebo for Pembrolizumab

    Administered as an IV infusion on Day 1 Q3W

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is the time from randomization to death due to any cause.

    Time frame: Up to approximately 65 months

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR).

    Time frame: Up to approximately 65 months

  2. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 as assessed by BICR.

    Time frame: Up to approximately 65 months

  3. Duration of Response (DOR)

    DOR is determined by disease assessment and is defined as the time from first response (CR or PR) to disease progression, or death from any cause, whichever occurs first.

    Time frame: Up to approximately 65 months

  4. Percentage of Participants Experiencing Adverse Events (AEs)

    Percentage of participants experiencing an AE defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study treatment.

    Time frame: Up to approximately 65 months

  5. Percentage of Participants Discontinuing Study Drug Due to AEs

    Percentage of participants discontinuing study treatment due to an AE.

    Time frame: Up to approximately 36 months

07

Study locations

28 sites
  • Cancer Hospital Chinese Academy of Medical Sciences ( Site 2421)
    Beijing, Beijing 100021, China
  • Peking Union Medical College Hospital ( Site 2425)
    Beijing, Beijing 100730, China
  • Fujian Medical University Union Hospital ( Site 2410)
    Fuzhou, Fujian 350001, China
  • Fujian Provincial Cancer Hospital ( Site 2414)
    Fuzhou, Fujian 350014, China
  • 900 Hospital of the Joint ( Site 2418)
    Fuzhou, Fujian 350025, China
  • The First Affiliated Hospital of Xiamen University ( Site 2430)
    Xiamen, Fujian 361003, China
  • Zhongshan Hospital Xiamen University ( Site 2447)
    Xiamen, Fujian 361004, China
  • Guangdong General Hospital ( Site 2431)
    Guangzhou, Guangdong 510080, China
  • Peking University Shenzhen Hospital ( Site 2442)
    Shenzhen, Guangdong 518036, China
  • Harbin Medical University Cancer Hospital ( Site 2401)
    Harbin, Heilongjiang 150081, China
  • Henan Cancer Hospital ( Site 2415)
    Zhengzhou, Henan 450008, China
  • Hubei Cancer Hospital ( Site 2434)
    Wuhan, Hubei 430079, China
  • Xiangya Hospital Central-South University ( Site 2419)
    Changsha, Hunan 410008, China
  • Hunan Cancer Hospital ( Site 2439)
    Changsha, Hunan 410013, China
  • Changzhou Cancer Hospital-Changzhou Fourth Peoples Hospital ( Site 2441)
    Changzhou, Jiangsu 213032, China
  • The 81st Hospital of PLA ( Site 2413)
    Nanjing, Jiangsu 210002, China
  • Jiangsu Cancer Hospital ( Site 2432)
    Nanjing, Jiangsu 210009, China
  • Yancheng First People s Hospital ( Site 2426)
    Yancheng, Jiangsu 224000, China
  • The First Affiliated Hospital of Nanchang University ( Site 2440)
    Nanchang, Jiangxi 330006, China
  • The First Hospital of Jilin University ( Site 2416)
    Chang chun, Jilin 130021, China
  • The Affiliated Hospital of Qingdao University ( Site 2405)
    Qingdao, Shandong 266061, China
  • Shanghai East Hospital ( Site 2403)
    Shanghai, Shanghai 200120, China
  • Zhongshan Hospital affiliated to Fudan University ( Site 2407)
    Shanghai, Shanghai 210000, China
  • 1st Affil hosp of Med College of Xi'an Jiaotong University ( Site 2428)
    XiAn, Shanxi 710061, China
  • Cancer Hospital Affiliated to Xinjiang Medical University ( Site 2420)
    Urumqi, Xinjiang 830001, China
  • Zhejiang Provincial People's Hospital ( Site 2446)
    Hangzhou, Zhejiang 310014, China
  • Sir Run Run Show Hospital ( Site 2427)
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital ( Site 2417)
    Hangzhou, Zhejiang 310022, China
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2018 (actual). Primary completion is estimated for Nov 2024, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2021
First posted
Apr 26, 2021
StartActual
Nov 8, 2018
Primary completionEst.
Nov 29, 2024
CompletionEst.
Nov 29, 2024
Last update
Dec 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04859582
Responsible party
Sponsor
First posted
Apr 26, 2021
Start date
Nov 8, 2018
Primary completion
Nov 29, 2024 (estimated)
Completion
Nov 29, 2024 (estimated)
Last update
Dec 16, 2021

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion